Drug Profile
Research programme: diabetes and obesity therapeutics - Genfit
Alternative Names: G 220; MKG 02; TGFTX 2Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Genfit; Merck Sante
- Developer Genfit
- Class
- Mechanism of Action Cytoplasmic and nuclear receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Obesity; Type 2 diabetes mellitus
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Obesity in France
- 04 Nov 2017 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in France
- 24 Mar 2009 Genfit acquires a research programme (MKG 02) on type 2 diabetes and obesity from Merck Sante